First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for …
WEBFeb 2, 2024 · Triplet therapy comprised intravenous atezolizumab 840 mg (days 1 and 15), oral ipatasertib 400 mg/day (days 1–21), and intravenous paclitaxel 80 mg/m (or nab-paclitaxel 100 mg/m; days 1, 8, and 15) every 28 days. Exploratory translational research aimed to elucidate mechanisms and molecular markers of …
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients …
WEBJan 13, 2021 · Based on results of the pivotal IMpower133 study, atezolizumab (anti–programmed death-ligand 1 [anti–PD-L1]) in combination with carboplatin and etoposide (CP/ET) was approved for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC).
Atezolizumab for First-Line Treatment of PD-L1–Selected …
WEBSep 30, 2020 · The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients...
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage …
WEBSep 25, 2018 · The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival...
WEBA clinical trial to compare ipatasertib plus atezolizumab and paclitaxel versus a placebo plus different combinations of ipatasertib, atezolizumab and paclitaxel in people with triple-negative breast
Clinical Trial: NCT04177108 - My Cancer Genome
WEBThis study will evaluate the efficacy, safety and pharmacokinetics of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) previously untreated in this setting.
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative …
WEBOct 20, 2018 · Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the...
CO41101 - Ipatasertib with atezolizumab and Paclitaxel in TNBC
WEBa phase iii, double-blind, placebo-controlled, randomized study of ipatasertib in combination with atezolizumab and paclitaxel as a treatment for patients with locally advanced unresectable or metastatic triple-negative breast cancer
Clinical Trial – Breast Cancer – Efficacy and Safety of Ipa... - Roche
WEBFeb 20, 2024 · This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting. Hoffmann-La Roche Sponsor. Phase 3 Phase. NCT04177108, CO41101, 2019-000810-12 Trial Identifier.
West Cancer Center
WEBHoffmann-La Roche CO41101 (1st line TNBC- IPATUNITY-170) Study Title A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.
Skip to content